Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Tumor-Agnostic 1Head & Neck 1Gynecologic 1

Conditions

Triple Negative Breast Neoplasms 23Breast Neoplasms 18Neoplasm Metastasis 2Her-2 Negative Breast Cancer 1HER2-negative Breast Cancer 1Gastrointestinal Neoplasms 1BRCA-Mutated Breast Carcinoma 1Advanced Triple Negative Breast Cancer 1

Interventions

Paclitaxel 50Capecitabine 50Trastuzumab 38Fulvestrant 31pembrolizumab 27Cyclophosphamide 27Carboplatin 27Gemcitabine 23Letrozole 21palbociclib 19Docetaxel 19Lapatinib 18Bevacizumab 18exemestane 17eribulin 15Everolimus 14abemaciclib 13Vinorelbine 13Nivolumab 13Magnetic Resonance Spectroscopy 12Cisplatin 12Anastrozole 12trastuzumab deruxtecan 11Zoledronic Acid 11Doxorubicin 11Albumin-Bound Paclitaxel 11olaparib 10Tamoxifen 10Specimen Handling 10Radiotherapy 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × camrelizumab × Breast × Clear all
NCT04355858 2022-07-26

MULAN

Fudan University

Phase 2 Unknown
319 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05438706 2022-06-30

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Fudan University

Phase 2 Unknown
70 enrolled
Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡